Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Pocket-Sized liver scanner could replace bulky MRI machines

NCT ID NCT05986916

First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 36 times

Summary

This study is testing a new, portable device called LiverScope that uses MRI-like technology to measure liver fat and other markers. Researchers will compare its accuracy to standard MRI and FibroScan in 50 adults with known or suspected nonalcoholic fatty liver disease (NAFLD). Participants undergo a one-time visit with scans and a blood draw. The goal is to see if this small, tabletop device can reliably diagnose liver disease outside of a hospital setting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NONALCOHOLIC FATTY LIVER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • University of California San Diego

    La Jolla, California, 92037, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

LiverScope® exam

What this could lead to

If successful, this portable device could make liver disease diagnosis easier and more accessible, reducing the need for large MRI machines.

What could go wrong

This is a small, early-stage study (50 participants) focused on comparing measurements, not on treatment outcomes. The device is not yet approved for clinical use.

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.